Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study.
S. Carraro (Padova, Italy), E. Di Palmo (Bologna, Italy), S. Barni (Firenze, Italy), V. Caldarelli (Reggio Emilia, Italy), G. De Castro (Roma, Italy), A. Di Marco (Roma, Italy), G. Fenu (Firenze, Italy), G. Giordano (Padova, Italy), A. Licari (Pavia, Italy), E. Lombardi (Firenze, Italy), P. Pirillo (Padova, Italy), M. Stocchero (Padova, Italy), A. Volpini (Ancona, Italy), S. Zanconato (Padova, Italy), F. Rusconi (Firenze, Italy)
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Carraro (Padova, Italy), E. Di Palmo (Bologna, Italy), S. Barni (Firenze, Italy), V. Caldarelli (Reggio Emilia, Italy), G. De Castro (Roma, Italy), A. Di Marco (Roma, Italy), G. Fenu (Firenze, Italy), G. Giordano (Padova, Italy), A. Licari (Pavia, Italy), E. Lombardi (Firenze, Italy), P. Pirillo (Padova, Italy), M. Stocchero (Padova, Italy), A. Volpini (Ancona, Italy), S. Zanconato (Padova, Italy), F. Rusconi (Firenze, Italy). Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study.. 2567
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: